# Connecticut Traffic Study Finds More Cannabinoid-Positive Fatalities > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/connecticut-cannabis-traffic-fatalities-study-2026/ > **Published:** 2026-09-08T12:49:26-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:45:11-04:00 > **Clinical Summary:** Connecticut cannabis traffic fatalities study finds higher cannabinoid positivity in some groups, without proving impairment or crash causation. --- CED Clinical Relevance #70 High Public Safety Relevance A peer-reviewed forensic analysis reports changing cannabinoid positivity among Connecticut traffic fatalities while explicitly warning that toxicology findings cannot establish impairment or causation. Clinical Insight | CED Clinic A retrospective Connecticut forensic study found higher cannabinoid positivity among several groups of traffic fatalities after adult-use legalization. The overall driver increase from 32.8 to 37.9 percent was not statistically significant, while the pedestrian increase from 11.0 to 20.6 percent was significant. Multiple substances were common, most often alcohol. The central clinical boundary is essential: cannabinoid detection does not establish acute impairment, recent use, or causation in an individual crash. These findings support continued surveillance and precise safety counseling. Cannabis SafetyDrivingToxicologyConnecticutLegalization AudiencePatients, clinicians, caregivers, public-health professionals, toxicologists, and policymakers evaluating cannabis and traffic safety Primary Topiccannabinoid toxicology findings in Connecticut traffic fatalities before and after adult-use legalization Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42509611/) A Connecticut forensic study found higher cannabinoid positivity among drivers and pedestrians killed in traffic incidents after adult-use legalization. The findings track toxicology patterns, not impairment, and the main driver comparison did not reach statistical significance. What This Study Teaches Us The study shows why traffic toxicology must be interpreted with precision. Cannabinoid positivity increased in several groups after legalization, but detection alone cannot establish recent use, driving impairment, or a causal role in a fatal crash. Why This Matters Patients and clinicians need a clear distinction between a positive cannabinoid test and evidence of impairment. The study adds useful surveillance data while also demonstrating how polysubstance findings and uncertain timing limit causal conclusions. Study SnapshotStudy TypeRetrospective forensic toxicology analysisData SourceConnecticut Office of the Chief Medical ExaminerStudy Period2018 through 2024, spanning 3.5 years before and after 2021 legalizationDrivers1,168 traffic fatalitiesPedestrians380 traffic fatalitiesOther Group52 suicide fatalities were also examinedDriver FindingCannabinoid positivity increased from 32.8% to 37.9%; P=0.0789Pedestrian FindingCannabinoid positivity increased from 11.0% to 20.6%; P=0.016Motorcyclist FindingA statistically significant increase followed legalizationPolysubstance ContextMultiple drugs were common, most frequently ethanolMajor Interpretation LimitCannabinoid concentrations and multidrug findings complicate attribution to impairmentPMID / DOI42509611 / 10.1097/PAF.0000000000001151 Clinical Bottom Line The Connecticut data document more cannabinoid-positive fatalities in some groups after legalization, but they do not show that cannabis caused the crashes or that a positive test proves impairment. What Changed Among Drivers Among 1,168 driver fatalities, cannabinoid positivity increased from 32.8 percent before legalization to 37.9 percent afterward. The reported P value was 0.0789, so the overall driver comparison did not meet the conventional threshold for statistical significance. The abstract separately reports a significant increase among motorcyclist deaths. The Pedestrian Signal Was Larger Among 380 pedestrian fatalities, cannabinoid positivity increased from 11.0 percent before legalization to 20.6 percent afterward. That comparison was statistically significant at P=0.016. The result identifies a surveillance signal, but it does not establish when cannabis was used or whether intoxication contributed to the fatal event. Detection Is Not the Same as Impairment Cannabinoid metabolites can remain detectable beyond the period of acute impairment, and concentration is difficult to translate into a reliable impairment threshold. The authors explicitly state that cannabinoid concentrations and frequent multidrug findings complicate attribution to impairment. A positive result therefore requires context rather than a simple alcohol-style interpretation. Alcohol and Other Drugs Complicate the Picture Multiple substances were commonly detected in cannabinoid-positive cases, most frequently ethanol. This matters because a fatal crash can involve several overlapping contributors. The abstract does not provide enough detail to separate the independent role of cannabis from alcohol, other drugs, roadway conditions, behavior, or broader changes in travel patterns. How Strong Is This Evidence? The study uses seven years of medical examiner data and includes substantial numbers of driver and pedestrian fatalities. It reports group-specific estimates, P values, and an explicit warning against equating cannabinoid detection with impairment. Where This Paper Deserves Skepticism This is a retrospective before-and-after analysis, not a controlled test of legalization effects. The accessible abstract cannot resolve timing of use, impairment at the crash, exposure trends in the wider population, pandemic-era driving changes, or the independent contribution of co-detected substances. What This Paper Does Not Show The study does not show that legalization caused fatal crashes, that every cannabinoid-positive person was impaired, that cannabis was the primary contributor to any individual death, or that blood concentration provides an alcohol-equivalent impairment cutoff. How This Fits With the Broader Clinical Conversation Traffic safety policy needs surveillance, but it also needs measurement tools that answer the right question. Toxicology positivity is useful for tracking exposure patterns and generating hypotheses, while impairment and crash causation require additional evidence. The practical public-health message remains straightforward. People should not drive after using intoxicating cannabis, and combining cannabis with alcohol can add risk. Those safety recommendations do not require treating every positive postmortem test as proof of impairment. Dr. Caplan’s Take *This paper is most useful when read with its own restraint. The signal is real enough to monitor, especially among pedestrians and motorcyclists, but the toxicology cannot tell us whether cannabis caused a particular crash.* *Patients deserve two clear messages at once. Avoid driving after intoxicating cannabis and avoid combining it with alcohol, but also understand that a positive cannabinoid test is not a precise measure of current impairment.* What a Careful Reader Should Take Away Treat these findings as a traffic-safety surveillance signal, not as proof that legalization or cannabis caused the observed fatalities. Evidence Interpretation Guide Table of Contents - [How to Interpret This Cannabinoid Toxicology Findings In Connecticut Traffic Fatalities Before And After Adult-Use Legalization Evidence Without Overstating It](#How_to_Interpret_This_Cannabinoid_Toxicology_Findings_In_Connecticut_Traffic_Fatalities_Before_And_After_Adult-Use_Legalization_Evidence_Without_Overstating_It)[A Four-Step Reading Frame](#A_Four-Step_Reading_Frame) - [Connecticut Traffic Toxicology Through Eight Safety Lenses](#Connecticut_Traffic_Toxicology_Through_Eight_Safety_Lenses)[Plan Around Impairment, Not Detection Windows](#Plan_Around_Impairment_Not_Detection_Windows) - [Counseling Needs More Than a Positive Test](#Counseling_Needs_More_Than_a_Positive_Test) - [A Before-and-After Study Tracks Association](#A_Before-and-After_Study_Tracks_Association) - [The Driver and Pedestrian Results Differ](#The_Driver_and_Pedestrian_Results_Differ) - [Cannabinoid Positivity Has a Timing Problem](#Cannabinoid_Positivity_Has_a_Timing_Problem) - [Alcohol Co-Detection Is Clinically Important](#Alcohol_Co-Detection_Is_Clinically_Important) - [Surveillance Should Improve Alongside Legal Access](#Surveillance_Should_Improve_Alongside_Legal_Access) - [The Next Studies Need Better Denominators](#The_Next_Studies_Need_Better_Denominators) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to Interpret This Cannabinoid Toxicology Findings In Connecticut Traffic Fatalities Before And After Adult-Use Legalization Evidence Without Overstating It A useful evidence report should let the signal breathe without inflating it. The right question is not whether the paper is positive or negative, but what kind of decision it can responsibly support. ### A Four-Step Reading Frame **Evidence type**Start by identifying whether the paper is a randomized trial, review, meta-analysis, observational study, or protocol. **Population**Ask whether the studied population matches the patient or clinical scenario involving cannabis, impairment, and traffic safety. **Outcome meaning**Look at what actually changed, how it was measured, and whether the change would matter in daily life. **Safety and uncertainty**Read limitations and adverse effects as part of the result, not as a footnote. The Research Question What does the current evidence suggest about cannabinoid toxicology findings in Connecticut traffic fatalities before and after adult-use legalization? The Patient Question Does this mean I should use cannabinoids for cannabis, impairment, and traffic safety? The Bottom Line The evidence can inform a careful conversation, but it does not replace individualized clinical care. CED Perspective Lens ## Connecticut Traffic Toxicology Through Eight Safety Lenses How to interpret cannabinoid-positive fatalities without confusing detection, impairment, and causation Lens OverviewEach perspective preserves the study's surveillance value while keeping its retrospective design and toxicology limits visible. #### Plan Around Impairment, Not Detection Windows A positive cannabinoid test may persist after the period of acute impairment, but that does not make driving soon after use safe. Patients should plan transportation before using intoxicating cannabis and should allow for delayed or unpredictable effects, especially with oral products. The study does not define a safe waiting interval or a concentration that proves fitness to drive. Product strength, route, dose, tolerance, sleep, medications, and alcohol can all matter. The practical decision should be conservative when alertness, reaction time, or coordination may be affected. Lens takeawayArrange transportation before use and do not rely on a laboratory cutoff to decide readiness to drive. #### Counseling Needs More Than a Positive Test Clinicians can use this study to explain the difference between exposure, recent intoxication, and functional impairment. The observed increases justify asking about route, timing, dose, frequency, co-use with alcohol, and driving plans without presenting toxicology as a complete answer. The abstract reports frequent multidrug detection, most often ethanol. That makes co-use counseling especially important. It does not provide patient-level causal estimates, so clinical discussion should stay focused on preventable risk rather than assuming cannabis was responsible for each fatal event. Lens takeawayPair nonjudgmental use history with explicit advice about driving and alcohol co-use. #### A Before-and-After Study Tracks Association The investigators compared medical examiner toxicology findings across 3.5 years before and after Connecticut legalized adult-use cannabis. This design can identify changes in cannabinoid positivity among people who died, and it can highlight groups that merit further surveillance. It cannot isolate legalization from other changes occurring between 2018 and 2024. The accessible abstract does not report enough detail to reconstruct testing protocols, missing data, concentration distributions, or time trends. Those boundaries prevent causal interpretation beyond the reported associations. Lens takeawayUse the study to describe changing toxicology patterns, not to estimate a causal legalization effect. #### The Driver and Pedestrian Results Differ Driver cannabinoid positivity increased from 32.8 to 37.9 percent, but the P value of 0.0789 means the overall comparison was not conventionally significant. The pedestrian increase from 11.0 to 20.6 percent was significant at P=0.016. Statistical significance does not establish clinical importance or causation, and lack of significance does not prove no difference. The separate motorcyclist result adds a subgroup signal, but the abstract does not provide the underlying counts or confidence intervals needed for a fuller precision assessment. Lens takeawayKeep each subgroup result distinct and avoid turning all increases into one generalized claim. #### Cannabinoid Positivity Has a Timing Problem Cannabinoid detection can reflect prior exposure without proving acute intoxication at the time of a crash. Unlike blood alcohol concentration, a cannabinoid value does not map cleanly onto functional impairment across occasional and frequent users. The authors emphasize that concentration interpretation and multidrug findings complicate attribution. The study therefore supports better toxicology surveillance but does not validate a single numeric impairment threshold. Functional observations and the total evidentiary context remain important when evaluating an individual case. Lens takeawayDo not translate a positive cannabinoid result into an automatic conclusion about acute impairment. #### Alcohol Co-Detection Is Clinically Important Multiple drugs were common among cannabinoid-positive fatalities, with ethanol the most frequent co-detected substance. The combination deserves attention because alcohol and cannabis can both affect skills needed for driving, even though this analysis cannot quantify their independent contributions. A prevention message can still be specific without overstating the study. Avoid driving after intoxicating cannabis, do not combine it with alcohol before travel, and discuss sedating medications that may add impairment. These recommendations are broader than the study’s causal reach but align with prudent risk reduction. Lens takeawayTreat alcohol, cannabis, and sedating medicines as a combined safety conversation before travel. #### Surveillance Should Improve Alongside Legal Access Legalization changes availability, reporting, consumer behavior, and enforcement context. The Connecticut findings support continued monitoring of drivers, motorcyclists, and pedestrians, with methods that distinguish exposure trends from acute impairment as well as current science allows. Policy responses should not assume that toxicology positivity alone explains a fatality. Better data collection can include concentration, specimen type, co-detected substances, crash circumstances, behavioral observations, and population exposure trends. The current abstract identifies the need but does not test a specific intervention. Lens takeawayBuild policy around richer surveillance and prevention, not a single toxicology marker. #### The Next Studies Need Better Denominators Future research should connect fatality toxicology with changing cannabis use prevalence, miles traveled, enforcement practices, testing consistency, and crash circumstances. Population denominators would help distinguish more exposure in the community from a changing risk per trip or per user. Prospective and multi-state work could test whether patterns differ by route, recency, concentration, age, road user type, and alcohol co-use. Better designs still may not create an alcohol-equivalent threshold, but they can narrow uncertainty and improve targeted prevention messages. Lens takeawayMeasure exposure, behavior, co-use, and crash context together to make surveillance more interpretable. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Connecticut+Traffic+Study+Finds+More+Cannabinoid-Positive+Fatalities&url=https%3A%2F%2Fcedclinic.com%2Fconnecticut-cannabis-traffic-fatalities-study-2026%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fconnecticut-cannabis-traffic-fatalities-study-2026%2F) [BlueSky](https://bsky.app/intent/compose?text=Connecticut+Traffic+Study+Finds+More+Cannabinoid-Positive+Fatalities%20https%3A%2F%2Fcedclinic.com%2Fconnecticut-cannabis-traffic-fatalities-study-2026%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Cannabinoid Positivity in Traffic Fatalities Before and After Cannabinoid Legalization: A Retrospective Analysis in Connecticut (2018-2024)](https://pubmed.ncbi.nlm.nih.gov/42509611/) Related Reading at CED ClinicContinue exploring the evidence[Can a Text-Message Intervention Reduce Cannabis-Impaired Driving? A New Randomized Trial](https://cedclinic.com/cannabis-impaired-driving-text-intervention/) Related CED coverage of a randomized intervention intended to reduce driving after cannabis use. [Read intervention evidence](https://cedclinic.com/cannabis-impaired-driving-text-intervention/)[Colorado Study Tests Cannabis Driving Effects in Adults 65 and Older](https://cedclinic.com/colorado-older-adults-cannabis-driving-study/) CED reporting on an experimental driving study focused on older adults who use cannabis. [Review driving study](https://cedclinic.com/colorado-older-adults-cannabis-driving-study/)[Cannabis Legalization Outcomes: What 329 Studies Found](https://cedclinic.com/cannabis-legalization-public-health-systematic-review/) A broader CED review of public-health outcomes reported across the legalization literature. [Read policy context](https://cedclinic.com/cannabis-legalization-public-health-systematic-review/) ## Frequently Asked Questions What did the Connecticut study examine? It examined cannabinoid toxicology findings among driver, pedestrian, and suicide fatalities recorded by the Connecticut Office of the Chief Medical Examiner from 2018 through 2024. How many traffic fatalities were included? The abstract reports 1,168 driver fatalities and 380 pedestrian fatalities, plus 52 suicide fatalities in a separate group. Did cannabinoid positivity increase among drivers? Yes. It increased from 32.8 percent before legalization to 37.9 percent afterward, but the overall driver comparison was not statistically significant at P=0.0789. What happened among pedestrians? Cannabinoid positivity increased from 11.0 percent to 20.6 percent among pedestrian fatalities, with P=0.016. What did the study report about motorcyclists? The abstract reports a statistically significant increase in cannabinoid-positive motorcyclist deaths after legalization. Does a positive cannabinoid test prove impairment? No. Cannabinoid detection can outlast acute effects, and the authors state that concentration interpretation complicates attribution to impairment. Did the study prove cannabis caused the crashes? No. This retrospective analysis identifies toxicology patterns and associations, not causation in individual crashes or a causal effect of legalization. Were other substances commonly detected? Yes. Multiple substances were common in cannabinoid-positive cases, most frequently ethanol. Was the full article available for this review? No. The peer-reviewed PubMed abstract and identifier record were reviewed, so claims are limited to details explicitly reported there. What is the practical safety takeaway? Do not drive after using intoxicating cannabis, avoid combining cannabis with alcohol before travel, and do not treat a laboratory result as a complete measure of impairment. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).